Kindred Biosciences
NASDAQ:KIN (8/27/2021, 7:19:13 PM)
After market: 9.26 +0.01 (+0.11%)9.25
+0.01 (+0.11%)
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company is headquartered in Burlingame, California and currently employs 63 full-time employees. The company went IPO on 2013-12-12. The firm is focused on developing therapies for pets. The firm's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The firm is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The firm is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The firm's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The firm's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
Kindred Biosciences
1555 Bayshore Hwy Ste 200
Burlingame CALIFORNIA 94010
P: 16507017901.0
CEO: Richard Chin
Employees: 63
Website: https://kindredbio.com/
NEW YORK, NY / ACCESSWIRE / August 17, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Sykes Enterprises, Incorporated (NASDAQ:SYKE) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Sitel Group for $54.00 per share. If you are a Sykes shareholder, click here to learn more about your rights and
Here you can normally see the latest stock twits on KIN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: